2011
DOI: 10.1016/j.jprot.2011.01.019
|View full text |Cite|
|
Sign up to set email alerts
|

Proteomics for development of vaccine

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
40
0

Year Published

2012
2012
2018
2018

Publication Types

Select...
4
3
1

Relationship

0
8

Authors

Journals

citations
Cited by 47 publications
(41 citation statements)
references
References 200 publications
0
40
0
Order By: Relevance
“…Bacterial Strains and Growth Conditions-The following N. gonorrhoeae strains were used in this study: FA1090 (22), MS11 (23), 1291 (24), F62 (25), FA19 (26), the clinical isolates LGB1, LG14, LG20, and LG26, which were collected from two public health clinics in Baltimore from 1991 to 1994 and differ in porB variable region type and pulsed gel electrophoresis patterns (21,27), 13 isolates from patients attending the Public Health-Seattle & King County Sexually Transmitted Disease clinic from 2011 to 2013 (supplemental Table S1), and the WHO 2015 reference strains (10,28,29).…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…Bacterial Strains and Growth Conditions-The following N. gonorrhoeae strains were used in this study: FA1090 (22), MS11 (23), 1291 (24), F62 (25), FA19 (26), the clinical isolates LGB1, LG14, LG20, and LG26, which were collected from two public health clinics in Baltimore from 1991 to 1994 and differ in porB variable region type and pulsed gel electrophoresis patterns (21,27), 13 isolates from patients attending the Public Health-Seattle & King County Sexually Transmitted Disease clinic from 2011 to 2013 (supplemental Table S1), and the WHO 2015 reference strains (10,28,29).…”
Section: Methodsmentioning
confidence: 99%
“…Pioneered by Rappuoli and colleagues, reverse vaccinology-which initially included genome and later proteome mining-has proven to be very successful in the discovery of vaccine candidates against many pathogenic bacteria (12)(13)(14)(15). In particular, these methodologies paved the way for the newly developed group B meningococcal vaccine, which was a formidable effort for many years.…”
mentioning
confidence: 99%
“…And the other way to enhance and/or modulate the host immune response is to deliver a vaccine with an appropriate adjuvant. The tremendous progress of proteomics during the past few years has contributed to every successive stage of antigen characterization (Adamczyk-Poplawska et al 2011).…”
Section: Discussionmentioning
confidence: 99%
“…Advanced proteomic technologies are currently employed to facilitate identification of changes in proteome accompanying tumorigenesis. Mapping of the protein and peptide spectra and comparison of proteomic profiles between tumorous and adjacent nontumorous tissue samples are currently implemented in the search for novel biomarkers with improved specificities for diagnosis, prognosis and treatment monitoring [91].…”
Section: Vaccine Developmentsmentioning
confidence: 99%